At Affinia Therapeutics, our purpose is to develop gene therapies that can have a transformative impact on people affected by devastating genetic diseases. Our proprietary platform enables us to methodically engineer novel AAV vectors and gene therapies that have remarkable tissue targeting and other properties. We are building world-class capabilities to discover, develop, manufacture and commercialize gene therapy products with an initial focus on muscle and central nervous system (CNS) diseases with significant unmet need.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/31/20 | $60,000,000 | Series A |
Alexandria Venture Investments Atlas Venture F-Prime Capital Partners  Lonza New Enterprise Associates Partners Innovation Fund | undisclosed |
